which is of no value in protein therapy; and 502(f)(1)—the labeling of the article failed to contain adequate directions for use since the article was worthless for any therapeutic purpose and no adequate directions for its use could be written.

DISPOSITION: 5-28-59. Default—destruction.

5872. Anterior pituitary solution. (F.D.C. No. 43114. S. No. 53-037 P.)

QUANTITY: 16 ctns., each containing 10 cartoned vials, at Huntington Park, Calif.

SHIPPED: 1-26-59, from Philadelphia, Pa., by Vitamix Corp.

LABEL IN PART: (Vial and ctn.) "30 cc. Multiple Dose Vial Anterior Pituitary Solution Sterile-Intramuscular Only * * * Manufactured in Phila. for Daylin Drugs, Inc., Distributors, Huntington Park, Calif. Each cc. Contains the water soluble extraction of dried glands derived from: Anterior Pituitary, fresh gland . . . 18½ grains Chlorobutanol (Chloral deriv.) . . . 0.5% Contains no known hormonal therapeutic activity Indications: Non-Specific Protein Therapy. Usual Dose: * * * Caution."

LIBELED: 4-16-59, S. Dist. Calif.

CHARGE: 502(a)—when shipped, the label statement "Indications: Non-Specific Protein Therapy" was false and misleading as applied to an article which is of no value in protein therapy; and 502(f)(1)—the labeling of the article failed to contain adequate directions for use since the article was worthless for any therapeutic purpose and no adequate directions for its use could be written.

DISPOSITION: 5-6-59. Default—destruction.

DRUGS FOR VETERINARY USE

5873. Medicated feed. (F.D.C. No. 43670. S. Nos. 47-553 P, 48-142 P.)

INFORMATION FILED: 12-7-59, W. Dist. N.Y., against Dean & Lee, a partnership, Horseheads, N.Y., and Harry L. Kahler, a partner.

SHIPPED: Between 9-13-58 and 2-13-59, from New York to Massachusetts.

LABEL IN PART: (Some bags) "100 Lbs. Net Pathfinder Medicated Jumbo Starter-Broiler * * * Active drug ingredients: Nicarbazin 0.0125%," and other bags were unlabeled.

CHARGE: (Labeled bags) 501(d)(2)—a product containing acetyl-(*p*-nitrophenyl)-sulfanilamide and 3,5-dinitrobenzamide had been substituted for nicarbazin which the article was represented to be; and (unlabeled bags) 502(b)—the article failed to bear a label containing (1) the name and place of business of the manufacturer, packer, or distributor, and (2) an accurate statement of the quantity of contents; 502(e)(2)—the article failed to bear a label containing the common or usual name of each active ingredient; 502(f)(1)—the article failed to bear labeling containing adequate directions for use; and (2) adequate warnings against unsafe dosage or methods or duration of administration or application in such manner and form as are necessary for the protection of users.

PLEA: Guilty.

DISPOSITION: 1-4-60. Partnership—$100 fine; individual—$100 fine which was remitted.